Yona Geffen, Ph.D., Chief Executive Officer
Dr. Geffen has more than 15 years of experience in leading drug development in biopharmaceutical companies specialized in the CNS field. Prior to joining Avraham Pharma, she served as an Executive Drug Development Director at BioLineRx (NASDAQ: BLRX), where she managed the development of a drug candidate for the treatment of schizophrenia and cognition. Before that she was involved in developing drugs for ALS, Huntington’s disease and Stroke. Dr. Geffen holds a Ph.D. in Immunology and Microbiology and an M.Sc. in business management, both from the Ben-Gurion University, Israel.
Moti Hacham, L.L.B, Chief Financial Officer
Mr. Hacham has more than 15 years of versatile financial and legal experience in the technology and biotech/pharma industries, including positions at Polyheal Ltd., CureTech Ltd. and Clal Life Sciences, a holding company of Clal Biotechnology Industries (TASE: CBI). Previously, he was an attorney in Ben-Shahar, Lekner & Co., one of Israel’s leading commercial law firms, and assistant to the Chief Financial Officer of Check Point Software Technologies (NASDAQ: CHKP), the worldwide leader in Internet security. Mr. Hacham has a B.A. degree in Economics from the Tel-Aviv University, and an LLB degree from Bar-Ilan University, Ramat-Gan, Israel. He is a member of the Israeli Bar Association.